What is Cann Group Limited?
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe.
CNGGF · Verdict
Limited reward · high risk
CNGGF's standout is volatility; balance sheet and cash flow weigh on the picture.
Based on 88% data coverage
CNGGF · Verdict
Above average
Current ratio 0.12
-74% free-cash-flow margin
-169% net margin · -401% ROE
Rev +5.7% CAGR · earnings -5.5%
Model-based scoring. For information only — not financial advice.
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 10.01M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.